Shanghai Matwings Technology Co., Ltd. ('Matwings'), a global leader in AI-driven protein design, announced the successful completion of Series A funding rounds, raising tens of millions of USD, led by Qiming Venture Partners.

Matwings is pioneering a new frontier in protein engineering with its proprietary AI-based general protein design platform, AccelProtein™, which directly predicts protein functionality beyond the structural data. By predicting functionality, AccelProtein™ offers a new approach for acquiring high-functioning proteins.

AccelProtein™ is built on the Pro-PRIME model, a breakthrough developed by a collaborative team led by Professor Liang Hong at Shanghai Jiao Tong University. After years of research focused on data collection, curation, and optimization, the team developed the Pro-series - an AI framework for protein design. Their work, titled "A General Temperature-Guided Language Model to Design Proteins of Enhanced Stability and Activity" was recently published in Science Advances.

A featured case of AccelProtein™'s impact is the design of a specialized Glycosyltransferase enzyme, which is used in the production of EPS-G7, a core material for pancreatitis screening. Within just 4 months, Matwings increased the enzyme's total glycosylation activity by 7 times, enhanced product specificity from 60% to 98%, and reduced hydrolytic activity by 33%. These improvements cut down the cost of EPS-G7 by 90%.

In another application, Matwings successfully engineered a super alkali-resistant affinity ligand (a nanobody) for affinity chromatography, improving alkali resistance by 3 folds, binding capacity over 100%, and heat stability by 8℃. This innovation saved millions of USD in CMC costs for a Matwings client. Additionally, scale-up production to 5000L has been successfully completed. Such advancement enables low-cost affinity chromatography purification a viable option for a wide range of biologics, bringing more cost-effective solutions for drug production.

Since 2021, Matwings has successfully delivered over 30 protein-engineering and enzyme-mining projects either proprietary (e.g., Enterokinase, Carboxypeptidase B, KEX2 Protease, Maltogenic Amylase, Subtilisin, Protein A, PETase, T7 RNA Polymerase, and phi29 DNA Polymerase) and co-developed with our stakeholders. These projects span across various applications, including drug innovation, in vitro diagnostics, nutrition and healthcare, food and beverage, and green energy.